Menu
Recruiting NCT07448467

Investigation of the Effectiveness of Progressive Resistance Exercise Training in the Management of Lymphedema.

No phase Interventional Lymphedema Breast Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: control, exercise.
Who it may be relevant to
Registry conditions: Lymphedema, Breast Cancer. Basic parameters: 18 years — 60 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Investigating the Effectiveness of Progressive Resistance Exercise Training in the Management of Lymphedema Developing After Breast Cancer Treatment: a Randomized Controlled Trial

Overview

This study aims to investigate the effect of progressive resistance exercise training on the clinical findings and functional outcomes of lymphedema in individuals who develop upper extremity lymphedema after breast cancer treatment (surgery, chemotherapy and/or radiotherapy).

Detailed description

The study is designed as a randomized controlled trial. Volunteers participating in the study will consist of individuals who have developed lymphedema after breast cancer and who agree to participate in the study. Volunteer female participants will be divided into 2 groups of equal numbers. Participants in the control group will receive lymphedema treatment, while participants in the exercise group will perform progressive resistance upper extremity exercises at home, 2 days a week for 12 weeks. All exercises will be performed with compression bandages. All participants will be evaluated before and after treatment using a hand dynamometer, the Disabilities of the Arm, Shoulder and Hand Scale, and the Lymphedema Quality of Life Questionnaire-Arm.

Interventions

  • Other control
    Classic lymphedema physiotherapy will be applied.
  • Other exercise
    In addition to classic lymphedema physiotherapy, a progressive resistance exercise training program will be implemented.

Primary outcome measures

  • LYMphedema Quality of Life [Time frame: 14 weeks]
  • Disabilities of the Arm, Shoulder and Hand [Time frame: 14 weeks]

Eligibility criteria

Inclusion criteria

  • Being between 18 and 60 years of age.
  • Being included in the study 3 months after undergoing surgery.
  • Being able to tolerate compression bandages or compression garments.

Exclusion criteria

\- Individuals who need to restart active cancer treatment during the study period. - Being within the first 3 months after surgery.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Turkey (Türkiye) · 1 center
  • Re-Heal Physiotherapist Sude BOYVADAOĞLU Healthy Living Center — Adana

Publications

  • Leon-Diaz R, Medina-Otero A. Prevention and Treatment of Postmastectomy Lymphedema: A Physiotherapy Perspective. Curr Oncol. 2025 Oct 3;32(10):555. doi: 10.3390/curroncol32100555. PMID 41149475
  • Shamsesfandabadi P, Shams Esfand Abadi M, Yin Y, Carpenter DJ, Peluso C, Hilton C, Coopey SB, Gomez J, Beriwal S, Champ CE. Resistance Training and Lymphedema in Breast Cancer Survivors. JAMA Netw Open. 2025 Jun 2;8(6):e2514765. doi: 10.1001/jamanetworkopen.2025.14765. PMID 40498485
  • Xue T, Zhang L, Zhang D. Exercise-based interventions for postoperative rehabilitation in breast cancer patients: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2025 Aug 22;104(34):e43705. doi: 10.1097/MD.0000000000043705. PMID 40859515

Identifiers

NCT: NCT07448467 · Uskudar96

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗